San Diego-based Sinopia Biosciences reported preclinical data in Science Translational Medicine showing that SB-0110, a selective PKA-II positive modulator, reduced levodopa-induced dyskinesia while preserving antiparkinsonian motor benefit in non-human primate models of Parkinson's disease. The company said SB-0110 is advancing through late-stage toxicology studies with first-in-human trials anticipated in 2027.
In non-human primate models with established dyskinesia, SB-0110 and its predecessor compound SB-0107 significantly reduced dyskinesia severity when administered alongside levodopa, according to the company, while potentiating levodopa's antiparkinsonian effects. Neither compound demonstrated meaningful activity across established Parkinson's drug targets, a broad panel of G protein-coupled receptor targets, or an off-target safety-liability panel, supporting a differentiated preclinical safety profile. No specific numerical endpoints, such as dyskinesia severity scores or quantified motor improvement values, were disclosed in the press release.
The study was conducted using an omics-guided discovery approach, in which transcriptomic profiles from drug perturbations were screened against transcriptomic signatures associated with levodopa's therapeutic and dyskinesia-linked effects — a method Sinopia describes as unbiased relative to pathway-focused screens. Findings are limited to preclinical models. Of note, the study was supported by grants from the National Institute of Neurological Disorders and Stroke, The Michael J. Fox Foundation for Parkinson’s Research (MJFF), and the National Institute of General Medical Sciences.